Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.
Read More…
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
Phone508-893-8999
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$120.77 million
Profitability
Miscellaneous
Employees519
Next Earnings Date2/26/2020 (Confirmed)
OptionableOptionable
Harvard Bioscience (NASDAQ:HBIO) Frequently Asked Questions
What is Harvard Bioscience's stock symbol?
Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."
How were Harvard Bioscience's earnings last quarter?
Harvard Bioscience, Inc. (NASDAQ:HBIO) announced its earnings results on Thursday, May, 2nd. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.01. The medical instruments supplier had revenue of $28.23 million for the quarter, compared to analysts' expectations of $28.50 million. Harvard Bioscience had a negative net margin of 2.45% and a positive return on equity of 5.22%. View Harvard Bioscience's Earnings History.
When is Harvard Bioscience's next earnings date?
How can I listen to Harvard Bioscience's earnings call?
Harvard Bioscience will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for HBIO?
2 equities research analysts have issued 12-month price objectives for Harvard Bioscience's stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate Harvard Bioscience's share price to reach $2.00 in the next year. This suggests that the stock has a possible downside of 23.7%. View Analyst Price Targets for Harvard Bioscience.
What is the consensus analysts' recommendation for Harvard Bioscience?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Harvard Bioscience.
Has Harvard Bioscience been receiving favorable news coverage?
Media stories about HBIO stock have trended very negative recently, InfoTrie reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Harvard Bioscience earned a coverage optimism score of -3.6 on InfoTrie's scale. They also assigned media coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Harvard Bioscience.
Who are some of Harvard Bioscience's key competitors?
Some companies that are related to Harvard Bioscience include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Charles River Laboratories Intl. (CRL), BIO-TECHNE (TECH), Bruker (BRKR), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM) and aTyr Pharma (LIFE).
What other stocks do shareholders of Harvard Bioscience own?
Who are Harvard Bioscience's key executives?
Harvard Bioscience's management team includes the folowing people:
- Mr. Jeffrey A. Duchemin, CEO, Pres & Director (Age 53)
- Ms. Kamalam Unninayar, Chief Financial Officer (Age 51)
- Mr. Russell J. Sylvia, VP of Global HR
- Mr. Corey Manchester, VP & Corp. Controller
Who are Harvard Bioscience's major shareholders?
Harvard Bioscience's stock is owned by a number of of institutional and retail investors. Top institutional investors include Engine Capital Management LP (8.43%), Royce & Associates LP (4.34%), Dalton Greiner Hartman Maher & Co. (4.13%), Acadian Asset Management LLC (2.79%), Renaissance Technologies LLC (1.41%) and Essex Investment Management Co. LLC (1.38%). Company insiders that own Harvard Bioscience stock include Bertrand Loy, George Uveges, James W Green, Jeffrey Duchemin, Katherine A Eade, Robert E Gagnon, Thomas W Loewald and Value Fund Lp Palogic. View Institutional Ownership Trends for Harvard Bioscience.
Which major investors are selling Harvard Bioscience stock?
HBIO stock was sold by a variety of institutional investors in the last quarter, including Engine Capital Management LP, Wedge Capital Management L L P NC, Royce & Associates LP, Marshall Wace LLP, Oxford Asset Management LLP, Algert Global LLC and Acadian Asset Management LLC. View Insider Buying and Selling for Harvard Bioscience.
Which major investors are buying Harvard Bioscience stock?
HBIO stock was acquired by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Vivaldi Asset Management LLC, Greenwood Capital Associates LLC, Essex Investment Management Co. LLC, Renaissance Technologies LLC, Zebra Capital Management LLC, Citigroup Inc. and Geode Capital Management LLC. Company insiders that have bought Harvard Bioscience stock in the last two years include Bertrand Loy, James W Green, Katherine A Eade, Thomas W Loewald and Value Fund Lp Palogic. View Insider Buying and Selling for Harvard Bioscience.
How do I buy shares of Harvard Bioscience?
Shares of HBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Harvard Bioscience's stock price today?
One share of HBIO stock can currently be purchased for approximately $2.62.
How big of a company is Harvard Bioscience?
Harvard Bioscience has a market capitalization of $99.74 million and generates $120.77 million in revenue each year. The medical instruments supplier earns $-2,920,000.00 in net income (profit) each year or $0.15 on an earnings per share basis. Harvard Bioscience employs 519 workers across the globe.View Additional Information About Harvard Bioscience.
What is Harvard Bioscience's official website?
How can I contact Harvard Bioscience?
Harvard Bioscience's mailing address is 84 OCTOBER HILL ROAD, HOLLISTON MA, 01746. The medical instruments supplier can be reached via phone at 508-893-8999 or via email at [email protected]
MarketBeat Community Rating for Harvard Bioscience (NASDAQ HBIO)
MarketBeat's community ratings are surveys of what our community members think about Harvard Bioscience and other stocks. Vote "Outperform" if you believe HBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
